Abstract:Ming-Ming Ma, 1, &ast Yao-Yao Xu, 2, &ast Li-Hua Sun, 1, &ast Wen-Jie Cui, 1 Miao Fan, 3 Su Zhang, 4 Lei Liu, 5 Ling-Zhi Wu, 6 Liu-Cheng Li 7 1 Department of Diagnostic Ultrasound & Echocardiography, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, People's Republic of China; 2 Department of Pharmacy, The People's Hospital of Pingyang, Wenzhou, 325400, People's Republic of China; 3 Department of Pharmacy, The First Affiliated Hospital of Ningbo University, Ningbo, 315010, People's Republic of China; 4 Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, People's Republic of China; 5 Department of Orthopaedics, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing, 312000, People's Republic of China; 6 Department of Pharmacy, The Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, 314000, People's Republic of China; 7 Department of Pharmacy, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liu-Cheng Li, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, People's Republic of China, Email Ling-Zhi Wu, The Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), No. 1882 South Central Road, Jiaxing, 314000, People's Republic of China, Email Surveillance of drug safety is an important aspect in the routine medical care. Adverse events caused by real-world drug utilization has become one of the leading causes of death and an urgent issue in the field of toxicology. Cardiovascular disease is now the leading cause of fatal diseases in most countries, especially in the elderly population who often suffer from multiple diseases and need long-term multidrug therapy. Among which, statins have been widely used to lower bad cholesterol and regress coronary plaque mainly in patients with hyperlipidemia and atherosclerotic cardiovascular diseases (ASCVD). Although the real-world benefits of statins are significant, different degrees and types of adverse drug reactions (ADR) such as liver dysfunction and muscle injury, have a great impact on the original treatment regimens as well as the quality of life. This review describes the epidemiology, mechanisms, early identification and post-intervention of statin-associated liver dysfunction and muscle injury based on the updated clinical evidence. It provides systematic and comprehensive guidance and necessary supplement for the clinical safety of statin use in cardiovascular diseases. Keywords: statin, cardiovascular diseases, liver dysfunction, muscle injury, countermeasures Drug safety, an urgent problem in clinical pharmacology and toxicology, is one of the primary health programs. 1,2 Drug exposure inevitably produces negative effects such as adverse drug reaction (ADR), which is related to many influencing factors such as age, drug categories, and route of administration. 3 ADR could damage patients' health, even delay the disease process, or lead to fatal consequences. The drug safety issues have become increasingly prominent. In recent years, the disease burden from cardiovascular diseases consistently ranks the primary contributor among all diseases. 4 There are many types of cardiovascular diseases with complex treatment strategies which include lipid-lowering drugs such as statins or its combination with other drugs. Recent pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials showed that statins decreased the risk of myocardial infarction (OR = 0.66, 95% CI: 0.61–0.71, P < 0.001), stroke (OR = 0.78, 95% CI: 0.72–0.84, P < 0.001), death from cardiovascular diseases (OR = 0.77, 95% CI: 0.72–0.83, P < 0.001) and all-cause death (OR = 0.83, 95% CI: 0.79–0.88, P < 0.001). 5 Statin combined with other lipid-lowering drug therapy could also significantly improve the anatomical and physiological function of the coronary arteries and down-regulate the re-hospitalization rate due to unstable angina in ST elevation myocardial infarction patients with non-infarct-related artery. 6 A retrospective study found that statins reduced the intubation, ICU admission, and mortality in COVID-19 patients. 7 These evidence reveal the importance of statins in lowering cardiovascular diseases risk and potential additional benefits of comorbidities. However, the i -Abstract Truncated-

Cardiac adverse events associated with statins in myocardial infarction patients: a pharmacovigilance analysis of the FDA Adverse Event Reporting System

Diabetic adverse events associated with three commonly used statins: a disproportionality analysis based on the FDA adverse event reporting system database

Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials

Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Safety of cardiovascular disease drugs approved between 2014 and 2021 in the US: a pharmacovigilance analysis

Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study

Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS)

Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention after Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses

Secondary Prevention of Major Cerebrovascular Events with Seven Different Statins: a Multi-Treatment Meta-Analysis

Adverse Events of Statin–fenofibric Acid Versus Statin Monotherapy: a Meta-Analysis of Randomized Controlled Trials

Effect of statins on blood pressure: Analysis on adverse events released by FDA

Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study

Safety assessment of ezetimibe: real-world adverse event analysis from the FAERS database

Reviews on Statin-associated Side Effects

The long-term usage of statin prevents adverse events in patients with atrial fibrillation

Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system

Research progress in the safety of statins

Real-world safety evaluation of atorvastatin: insights from the US FDA adverse event reporting system (FAERS)

Statin-Associated Liver Dysfunction and Muscle Injury: epidemiology, Mechanisms, and Management Strategies

Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database